Dr. Sarmad Sadeghi
Claim this profileUSC / Norris Comprehensive Cancer Center
Studies Skin Cancer
Studies Transitional Cell Carcinoma
5 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Sarmad Sadeghi is currently running
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
sEphB4-HSA + Pembrolizumab
for Cancer
This is a multi-cohort single arm phase II/screening trial of the combination of a fusion protein that binds EphrinB2 and blocks interaction with cell surface EphB receptors (sEphB4-HSA) in combination with an anti-PD1 antibody (MK-7435 / Pembrolizumab) for treatment of patients with specific solid tumors. There will be four cohorts in this trial: 1. Cohort A, phase II 2nd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. 2. Cohort B, phase II 3rd line trial of sEphB4-HSA and pembrolizumab for platinum refractory metastatic urothelial carcinoma. 3. Cohort C, phase II neoadjuvant trial of sEphB4-HSA and pembrolizumab for locally advanced muscle invasive urothelial carcinoma. 4. Cohort D, phase II neoadjuvant trial of sEphB4-HSA and pembrolizumab for locally advanced prostate cancer.
Recruiting1 award Phase 223 criteria
More about Sarmad Sadeghi
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Sarmad Sadeghi has experience with
- Pembrolizumab
- Recombinant EphB4-HSA Fusion Protein
- Anti-OX40 Antibody PF-04518600
- Axitinib
- Docetaxel
- Eribulin Mesylate
Breakdown of trials Sarmad Sadeghi has run
Skin Cancer
Transitional Cell Carcinoma
Bladder Cancer
Kidney Cancer
Urothelial Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sarmad Sadeghi specialize in?
Sarmad Sadeghi focuses on Skin Cancer and Transitional Cell Carcinoma. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Sarmad Sadeghi currently recruiting for clinical trials?
Yes, Sarmad Sadeghi is currently recruiting for 4 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Sarmad Sadeghi has studied deeply?
Yes, Sarmad Sadeghi has studied treatments such as Pembrolizumab, Recombinant EphB4-HSA Fusion Protein, Anti-OX40 Antibody PF-04518600.
What is the best way to schedule an appointment with Sarmad Sadeghi?
Apply for one of the trials that Sarmad Sadeghi is conducting.
What is the office address of Sarmad Sadeghi?
The office of Sarmad Sadeghi is located at: USC / Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States. This is the address for their practice at the USC / Norris Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.